FDA Alert on the Anti-Diabetes Drug Avandia:
Risk of Heart Attack

The U.S. Food and Drug Administration (FDA) has issued a warning regarding Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Data from clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia.

The FDA recommends that people who are prescribed Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack, should discuss with a medical profession this new warning as they weigh the treatment options for their type 2 diabetes.

The FDA also stresses that there is an inherent risk to switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments.

Avandia is manufactured by GlaxoSmithKline, which is based in Research Triangle Park, N.C.

If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.

Click To Talk To Us Online

see also:

9.12.07 Study Analysis New Study Highlights Heart Risks to Taking GlaxoSmithKline's Avandia
Study: Avandia increases heart attack risk by more than 40 percent

FDA Warning, 5.22.07 FDA Alert on the Anti-Diabetes Drug Avandia: Risk of Heart Attack
Risks to taking the drug Avandia include heart attack and chest pain

FDA Warning, 6.6.07 FDA Issues Strictest Warning on Prescription Diabetes Drug Avandia
FDA Calls for Toughest Warning to be Placed on Avandia Prescription